Bilimsel Makale Arama | NeuralCipher AI

Kaynak kaydı

Biologic Frameworks for Synucleinopathies: Contributions of the Parkinson's Progression Markers Initiative.

Chahine LM, Alcalay RN, Brown EG, Chowdhury S, Coffey CS, Foroud T, Frasier M, Galasko D, Merchant KM, Mollenhauer B, Tolosa E, Pavese N, Tropea TF, Marek K, Simuni T, Parkinson's Progression Markers Initiative.

Ann Neurol · 2026-05-06

DOI: 10.1002/ana.78249PMID: 42089472

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

From Parkinson's Progression Markers Initiative to Parkinson's Precision Medicine Initiative: Still PPMI.

Marek K, Chowdhury S, Tropea TF, Parkinson's Progression Markers Initiative.

Ann Neurol · 2026-05-05

DOI: 10.1002/ana.78242PMID: 42083870

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Differential predictors of motor and cognitive progression in Parkinson's disease: a 2-year prospective multimodal cohort study.

Wang A, Zeng X, Wan L.

Neurol Res · 2026-04-30

DOI: 10.1080/01616412.2026.2666880PMID: 42059577

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Clinical characteristics and predictors of disease progression in parkinson's disease in a cohort of patients in the ashanti region, Ghana.

Obese V, Nkum B, Akassi J, Agbenorku M, Adamu S, Opare-Addo PA, Bilson AJ, Ababio H, Rizig M, Sarfo FS.

Equity Neurosci · 2026-04-30

DOI: 10.1016/j.neuros.2026.100051PMID: 42245155

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Return of Individual Research Information in the Parkinson's Progression Markers Initiative.

Tropea TF, Brodkin K, Brumm MC, Carley JK, Destro C, Flagg E, Heathers LEA, Henry B, Lemon LP, Kuhl MM, McMahon BA, Miller M, Myers H, Stanley CE, Talarico JM, Pico C, Chahine LM, Siderowf A, Marek K, Foroud T, Parkinson's Progression Markers Initiative.

Ann Neurol · 2026-04-29

DOI: 10.1002/ana.78228PMID: 42057343

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Progressive Resistance Training in Parkinson's Disease: An Umbrella Review Examining the Role of Methodological Adherence and Training Progression Principles in Clinical Outcome.

Rozenbaum Y, Hutzler Y, Barak S.

J Funct Morphol Kinesiol · 2026-04-28

DOI: 10.3390/jfmk11020178PMID: 42200884

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Selective vulnerability of monoaminergic neurons and network spread of alpha-synuclein jointly explain pathology progression in Parkinson's disease models.

Teshome S, Torok J, Mezias C, Gupta A, Raj A.

Neurobiol Dis · 2026-04-27

DOI: 10.1016/j.nbd.2026.107403PMID: 42055257

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Insights Gained From the PPMI Brain Donation Program.

Foroud T, Heathers LEA, Bukhari S, Poston KL, Antonopoulos G, Mantravadi K, Rumbaugh M, Mac Donald CL, Latimer CS, Tropea TF, Marek K, Keene CD, Montine TJ, Parkinson's Progression Markers Initiative.

Ann Neurol · 2026-04-26

DOI: 10.1002/ana.78229PMID: 42036930

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

[A "prion mechanism" involved in the progression of Parkinson's disease: towards innovative therapeutic approaches?]

Baron T.

Med Sci (Paris) · 2026-04-24

DOI: 10.1051/medsci/2026058PMID: 42028943

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Association Between Cardiovascular Risk Factors and the Progression of Motor and Non-Motor Symptoms in Parkinson's Disease: A Five-Year Cohort Study.

Chen J, Chen J, Zhao Z, Zhao D, Chen B, Wang Q, Li Y, Bai C, Guo X, Wang J, Yuan J.

J Clin Med · 2026-04-23

DOI: 10.3390/jcm15093217PMID: 42122947

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined Synucleinopathy.

Weintraub D, York MK, Dobkin R, Nair AR, Kurth R, Lafontant DE, Caspell-Garcia C, Alcalay RN, Brown EG, Chahine LM, Coffey C, Foroud T, Galasko D, Kieburtz K, Marek K, Merchant K, Mollenhauer B, Poston KL, Siderowf A, Simonet C, Simuni T, Tanner CM, Tropea TF, Videnovic A, Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol · 2026-04-21

DOI: 10.1002/acn3.70399PMID: 42015618

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Partnering With Participant Advisors on the Parkinson's Progression Markers Initiative.

McGuire Kuhl M, Destro C, Dobkin RD, Tropea TF, Brodkin K, Flagg E, Lemon LP, Henry B, McMahon BA, Stanley CE, Matthews-McGee A, Heathers LEA, Miller M, Myers H, Foroud T, Pico C, Kelliher C, Kopil CM, Dance A, Duggan B, Goldstein FS, Robinson BS, Robinson J, Acevedo M, Clark M, Hidaka C, Moran J, Lugo P, Sugihara S, Paulson RD, Alongi PT, Comerci L, Kwok K, Kramer H, Marek K, Parkinson's Progression Markers Initiative.

Ann Neurol · 2026-04-21

DOI: 10.1002/ana.78220PMID: 42012017

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.

1.057 makale bulundu

Biologic Frameworks for Synucleinopathies: Contributions of the Parkinson's Progression Markers Initiative.

From Parkinson's Progression Markers Initiative to Parkinson's Precision Medicine Initiative: Still PPMI.

Differential predictors of motor and cognitive progression in Parkinson's disease: a 2-year prospective multimodal cohort study.

Clinical characteristics and predictors of disease progression in parkinson's disease in a cohort of patients in the ashanti region, Ghana.

Return of Individual Research Information in the Parkinson's Progression Markers Initiative.

Progressive Resistance Training in Parkinson's Disease: An Umbrella Review Examining the Role of Methodological Adherence and Training Progression Principles in Clinical Outcome.

Selective vulnerability of monoaminergic neurons and network spread of alpha-synuclein jointly explain pathology progression in Parkinson's disease models.

Insights Gained From the PPMI Brain Donation Program.

[A "prion mechanism" involved in the progression of Parkinson's disease: towards innovative therapeutic approaches?]

Association Between Cardiovascular Risk Factors and the Progression of Motor and Non-Motor Symptoms in Parkinson's Disease: A Five-Year Cohort Study.

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined Synucleinopathy.

Partnering With Participant Advisors on the Parkinson's Progression Markers Initiative.

Filtreler